Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including:

• CD19-directed CAR T-cell therapies
• Next-generation CD19 bispecific antibodies
• The evolving role of allogeneic transplant

Presenters:

Ibrahim Aldoss, MD
Associate Professor
Division of Leukemia
Department of Hematology/HCT
City of Hope National Medical Center
Duarte, California

Bijal Shah, MD, MS
Senior Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Link to full program: 
https://bit.ly/4cRjiUi

Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.